Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 54

Sort by

Sort Order Select

Meeting Abstracts

355-OR: Glycemic Outcomes with CGM Use in Patients with Type 2 Diabetes—Real-World Analysis

SATISH K. GARG, IRL B. HIRSCH, ENRICO REPETTO, BRIAN ULMER, CHRISTOPHER PERKINS, JANET K. SNELL-BERGEON, RICHARD M. BERGENSTAL

Diabetes 2024;73(Supplement_1):355-OR

https://doi.org/10.2337/db24-355-OR

Published: 24 June 2024

View articletitled, 355-OR: Glycemic Outcomes with CGM Use in Patients with Type 2 Diabetes—Real-World Analysis

Meeting Abstracts

983-P: Long-Term Improvement in CGM-Measured Glycemic Control in Adults with Type 2 Diabetes Not Treated with Insulin—Real-World Data

JENNIFER E. LAYNE, LAUREN H. JEPSON, ALEXANDER CARITE, RICHARD M. BERGENSTAL

Diabetes 2024;73(Supplement_1):983-P

https://doi.org/10.2337/db24-983-P

Published: 21 June 2024

View articletitled, 983-P: Long-Term Improvement in CGM-Measured Glycemic Control in Adults with Type 2 Diabetes Not Treated with Insulin—Real-World Data

Meeting Abstracts

612-P: Impact of Continuous Glucose Monitoring (CGM) vs. Blood Glucose Monitoring (BGM) on Dietary Adherence and Weight during a Medically Supervised Ketogenic Diet Program (MSKDP) in People with Type 2 Diabetes (T2D)

HOLLY J. WILLIS, AMY L. MCKENZIE, CAROLINE G.P. ROBERTS, STEPHEN E. ASCHE, SHANNON KRIZKA, REBECCA N. ADAMS, BRITTANIE M. VOLK, ALISON R. ZOLLER, SHAMINIE J. ATHINARAYANAN, RICHARD M. BERGENSTAL

Diabetes 2024;73(Supplement_1):612-P

https://doi.org/10.2337/db24-612-P

Published: 14 June 2024

View articletitled, 612-P: Impact of Continuous Glucose Monitoring (CGM) vs. Blood Glucose Monitoring (BGM) on Dietary Adherence and Weight during a Medically Supervised Ketogenic Diet Program (MSKDP) in People with Type 2 Diabetes (T2D)

Meeting Abstracts

611-P: Effect of Continuous Glucose Monitoring (CGM) vs. Blood Glucose Monitoring (BGM) during a Nutrition Intervention on Time in Range (TIR)

HOLLY J. WILLIS, STEPHEN E. ASCHE, AMY L. MCKENZIE, REBECCA N. ADAMS, SHANNON KRIZKA, CAROLINE G.P. ROBERTS, BRITTANIE M. VOLK, SHAMINIE J. ATHINARAYANAN, ALISON R. ZOLLER, RICHARD M. BERGENSTAL

Diabetes 2024;73(Supplement_1):611-P

https://doi.org/10.2337/db24-611-P

Published: 14 June 2024

View articletitled, 611-P: Effect of Continuous Glucose Monitoring (CGM) vs. Blood Glucose Monitoring (BGM) during a Nutrition Intervention on Time in Range (TIR)

Meeting Abstracts

1927-LB: Impact of Continuous Glucose Monitoring Use on Hospitalizations in People with Type 2 Diabetes—Real-World Analysis

SATISH K. GARG, IRL B. HIRSCH, ENRICO REPETTO, JANET K. SNELL-BERGEON, BRIAN ULMER, CHRISTOPHER PERKINS, RICHARD M. BERGENSTAL

Diabetes 2024;73(Supplement_1):1927-LB

https://doi.org/10.2337/db24-1927-LB

Published: 14 June 2024

View articletitled, 1927-LB: Impact of Continuous Glucose Monitoring Use on Hospitalizations in People with Type 2 Diabetes—Real-World Analysis

Meeting Abstracts

945-P: Safety and Glycemic Outcomes of Adults with Type 2 Diabetes (T2D) in a MiniMed Advanced Hybrid Closed-Loop (AHCL) System Trial

ANUJ BHARGAVA, JAMES THRASHER, BRUCE W. BODE, MARK L. WARREN, RICHARD M. BERGENSTAL, MICHAEL DEMPSEY, JOHN H. REED, HAOXI MA, ASHLEIGH KEITER, TONI L. CORDERO, JENNIFER MCVEAN, JOHN SHIN, ANDREW S. RHINEHART, ROBERT A. VIGERSKY, MINIMED™ AHCL IN TYPE 2 DIABETES STUDY GROUP

Diabetes 2024;73(Supplement_1):945-P

https://doi.org/10.2337/db24-945-P

Published: 14 June 2024

View articletitled, 945-P: Safety and Glycemic Outcomes of Adults with Type 2 Diabetes (T2D) in a MiniMed Advanced Hybrid Closed-Loop (AHCL) System Trial

Meeting Abstracts

196-OR: A Scalable Application of Artificial Intelligence (AI) to Transform Type 2 Diabetes Management in Clinical Practice

MARK L. WARREN, RICHARD M. BERGENSTAL, MATTHEW HAGER, ERAN BASHAN, ISRAEL HODISH

Diabetes 2024;73(Supplement_1):196-OR

https://doi.org/10.2337/db24-196-OR

Published: 14 June 2024

View articletitled, 196-OR: A Scalable Application of Artificial Intelligence (AI) to Transform Type 2 Diabetes Management in Clinical Practice

Meeting Abstracts

818-P: Effects of Insulin Efsitora Alfa (Efsitora) on Frequency and Severity of Hypoglycemia (Hypo) Under Conditions of Increased Hypo Risk Compared with Glargine in Type 2 Diabetes (T2D)

TIM HEISE, GRIT ANDERSEN, EDWARD J. PRATT, JENNIFER LEOHR, TSUYOSHI FUKUDA, QIANQIAN WANG, CHRISTOF M. KAZDA, JULIANA M. BUE-VALLESKEY, RICHARD M. BERGENSTAL

Diabetes 2024;73(Supplement_1):818-P

https://doi.org/10.2337/db24-818-P

Published: 14 June 2024

View articletitled, 818-P: Effects of Insulin Efsitora Alfa (Efsitora) on Frequency and Severity of Hypoglycemia (Hypo) Under Conditions of Increased Hypo Risk Compared with Glargine in Type 2 Diabetes (T2D)

Meeting Abstracts

67-OR: Postprandial Glycemic Patterns throughout Uncomplicated Pregnancies

ANDERS L. CARLSON, ZOEY LI, ROY BECK, CELESTE DURNWALD, ELIZABETH NORTON, RICHARD M. BERGENSTAL, MARY L. JOHNSON, SEAN M. DUNNIGAN, MATHEW BANFIELD, KATIE J. KRUMWIEDE, JUDY SIBAYAN, PETER CALHOUN

Diabetes 2024;73(Supplement_1):67-OR

https://doi.org/10.2337/db24-67-OR

Published: 14 June 2024

View articletitled, 67-OR: Postprandial Glycemic Patterns throughout Uncomplicated Pregnancies

Meeting Abstracts

63-OR: Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes

ZOEY LI, ROY BECK, CELESTE DURNWALD, ANDERS L. CARLSON, ELIZABETH NORTON, RICHARD M. BERGENSTAL, MARY L. JOHNSON, SEAN M. DUNNIGAN, MATHEW BANFIELD, KATIE J. KRUMWIEDE, JUDY SIBAYAN, PETER CALHOUN

Diabetes 2024;73(Supplement_1):63-OR

https://doi.org/10.2337/db24-63-OR

Published: 14 June 2024

View articletitled, 63-OR: Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes

Meeting Abstracts

764-P: Time in Range and Time in Tight Range in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 CGM Substudy

RICHARD M. BERGENSTAL, ÁNGEL RODRÍGUEZ, BRIAN D. BENNEYWORTH, CLAUDIA NICOLAY, KATELYN BROWN

Diabetes 2023;72(Supplement_1):764-P

https://doi.org/10.2337/db23-764-P

Published: 20 June 2023

View articletitled, 764-P: Time in Range and Time in Tight Range in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 CGM Substudy

Meeting Abstracts

263-OR: Older Adults Benefit from Virtual Support for CGM Use but Require Longer Visits

RUTH S. WEINSTOCK, ZACHARY THOMPSON, RICHARD M. BERGENSTAL, TERRA L. CUSHMAN, ROBIN L. GAL, CRAIG KOLLMAN, DAVIDA F. KRUGER, KOREY K. HOOD, MARY L. JOHNSON, TERESA S. MCARTHUR, BETH A. OLSON, SEAN OSER, TAMARA OSER, DAN RAGHINARU, ROY BECK, GRAZIA ALEPPO

Diabetes 2023;72(Supplement_1):263-OR

https://doi.org/10.2337/db23-263-OR

Published: 20 June 2023

View articletitled, 263-OR: Older Adults Benefit from Virtual Support for CGM Use but Require Longer Visits

Meeting Abstracts

172-OR: Normative CGM Glucose Levels throughout Gestation in Patients with Uncomplicated Pregnancies

ANDERS L. CARLSON, ROY BECK, ZOEY LI, ELIZABETH NORTON, RICHARD M. BERGENSTAL, MARY L. JOHNSON, SEAN DUNNIGAN, MATTHEW BANFIELD, KATIE J. KRUMWIEDE, JUDY SIBAYAN, PETER CALHOUN, CELESTE DURNWALD

Diabetes 2023;72(Supplement_1):172-OR

https://doi.org/10.2337/db23-172-OR

Published: 20 June 2023

View articletitled, 172-OR: Normative CGM Glucose Levels throughout Gestation in Patients with Uncomplicated Pregnancies

Meeting Abstracts

149-LB: Telemedicine Intervention Impact on Diabetes Self-Management—Twelve-Month Virtual Diabetes Specialty Clinic (VDISC) Study Outcomes

ROBIN L. GAL, DAN RAGHINARU, GRAZIA ALEPPO, BETH A. OLSON, DAVIDA F. KRUGER, RICHARD M. BERGENSTAL, RUTH S. WEINSTOCK, AMY BRADSHAW, TERESA S. MCARTHUR, SEAN OSER, TAMARA OSER, KOREY K. HOOD, TERRA L. CUSHMAN, MARY L. JOHNSON, CRAIG KOLLMAN, ROY BECK

Diabetes 2023;72(Supplement_1):149-LB

https://doi.org/10.2337/db23-149-LB

Published: 20 June 2023

View articletitled, 149-LB: Telemedicine Intervention Impact on Diabetes Self-Management—Twelve-Month Virtual Diabetes Specialty Clinic (VDISC) Study Outcomes

Meeting Abstracts

85-LB: CGM Outcomes and Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1 Exploratory Analysis

RICHARD M. BERGENSTAL, SARA K. WATT, ANA LAURA S.A. MATOS, ILDIKO LINGVAY, JULIA K. MADER, TOMOYUKI NISHIDA, JULIO ROSENSTOCK

Diabetes 2023;72(Supplement_1):85-LB

https://doi.org/10.2337/db23-85-LB

Published: 20 June 2023

View articletitled, 85-LB: CGM Outcomes and Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1 Exploratory Analysis

Meeting Abstracts

173-OR: CGM-Measured Differences in Pregnancies With vs. Without Gestational Diabetes (GDM) and Adverse Perinatal Outcomes (APO)

CELESTE DURNWALD, ROY BECK, ZOEY LI, ELIZABETH NORTON, RICHARD M. BERGENSTAL, MATTHEW BANFIELD, MARY L. JOHNSON, SEAN DUNNIGAN, JUDY SIBAYAN, PETER CALHOUN, ANDERS L. CARLSON

Diabetes 2023;72(Supplement_1):173-OR

https://doi.org/10.2337/db23-173-OR

Published: 20 June 2023

View articletitled, 173-OR: CGM-Measured Differences in Pregnancies With vs. Without Gestational Diabetes (GDM) and Adverse Perinatal Outcomes (APO)

Meeting Abstracts

1174-P: Characterization of Glucose Levels in Pregnancy Measured by Blood Glucose Testing or CGM Monitoring after a 50-g Screening or a 75-g or 100-g OGTT

ANDERS L. CARLSON, ROY BECK, ZOEY LI, ELIZABETH NORTON, RICHARD M. BERGENSTAL, MARY L. JOHNSON, SEAN DUNNIGAN, MATTHEW BANFIELD, KATIE J. KRUMWIEDE, JUDY SIBAYAN, PETER CALHOUN, CELESTE DURNWALD

Diabetes 2023;72(Supplement_1):1174-P

https://doi.org/10.2337/db23-1174-P

Published: 20 June 2023

View articletitled, 1174-P: Characterization of Glucose Levels in Pregnancy Measured by Blood Glucose Testing or CGM Monitoring after a 50-g Screening or a 75-g or 100-g OGTT

Meeting Abstracts

1031-P: Virtual Clinic Support—Patient-Reported Outcome Benefits

KOREY K. HOOD, RICHARD M. BERGENSTAL, TERRA L. CUSHMAN, ROBIN L. GAL, CRAIG KOLLMAN, DAVIDA F. KRUGER, MARY L. JOHNSON, TERESA S. MCARTHUR, BETH A. OLSON, SEAN OSER, TAMARA OSER, DAN RAGHINARU, ZACHARY THOMPSON, RUTH S. WEINSTOCK, ROY BECK, GRAZIA ALEPPO

Diabetes 2023;72(Supplement_1):1031-P

https://doi.org/10.2337/db23-1031-P

Published: 20 June 2023

View articletitled, 1031-P: Virtual Clinic Support—Patient-Reported Outcome Benefits

Meeting Abstracts

728-P: Glycemic Variability of Tirzepatide vs. Insulin Degludec in People with Type 2 Diabetes Using Continuous Glucose Monitoring (SURPASS-3 CGM)

RICHARD M. BERGENSTAL, AMY BARTEE, MELTEM ZEYTINOGLU, ROSS BRAY, SHERYL ALLEN, KATELYN BROWN

Diabetes 2022;71(Supplement_1):728-P

https://doi.org/10.2337/db22-728-P

Published: 01 June 2022

View articletitled, 728-P: Glycemic Variability of Tirzepatide vs. Insulin Degludec in People with Type 2 Diabetes Using Continuous Glucose Monitoring (SURPASS-3 CGM)

Meeting Abstracts

105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial

RICHARD M. BERGENSTAL, STEVEN EDELMAN, PRATIK CHOUDHARY, THOMAS DANNE, ERIC RENARD, JUKKA WESTERBACKA, BHASWATI MUKHERJEE, PASCALINE PICARD, VALERIE PILORGET, TADEJ BATTELINO

Diabetes 2022;71(Supplement_1):105-LB

https://doi.org/10.2337/db22-105-LB

Published: 01 June 2022

View articletitled, 105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial

Update search

NARROW

Format

Journal

Article Type

Topics

Issue Section

Date

Availability

355-OR: Glycemic Outcomes with CGM Use in Patients with Type 2 Diabetes—Real-World Analysis

983-P: Long-Term Improvement in CGM-Measured Glycemic Control in Adults with Type 2 Diabetes Not Treated with Insulin—Real-World Data

612-P: Impact of Continuous Glucose Monitoring (CGM) vs. Blood Glucose Monitoring (BGM) on Dietary Adherence and Weight during a Medically Supervised Ketogenic Diet Program (MSKDP) in People with Type 2 Diabetes (T2D)

611-P: Effect of Continuous Glucose Monitoring (CGM) vs. Blood Glucose Monitoring (BGM) during a Nutrition Intervention on Time in Range (TIR)

1927-LB: Impact of Continuous Glucose Monitoring Use on Hospitalizations in People with Type 2 Diabetes—Real-World Analysis

945-P: Safety and Glycemic Outcomes of Adults with Type 2 Diabetes (T2D) in a MiniMed Advanced Hybrid Closed-Loop (AHCL) System Trial

196-OR: A Scalable Application of Artificial Intelligence (AI) to Transform Type 2 Diabetes Management in Clinical Practice

818-P: Effects of Insulin Efsitora Alfa (Efsitora) on Frequency and Severity of Hypoglycemia (Hypo) Under Conditions of Increased Hypo Risk Compared with Glargine in Type 2 Diabetes (T2D)

67-OR: Postprandial Glycemic Patterns throughout Uncomplicated Pregnancies

63-OR: Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes

764-P: Time in Range and Time in Tight Range in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 CGM Substudy

263-OR: Older Adults Benefit from Virtual Support for CGM Use but Require Longer Visits

172-OR: Normative CGM Glucose Levels throughout Gestation in Patients with Uncomplicated Pregnancies

149-LB: Telemedicine Intervention Impact on Diabetes Self-Management—Twelve-Month Virtual Diabetes Specialty Clinic (VDISC) Study Outcomes

85-LB: CGM Outcomes and Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1 Exploratory Analysis

173-OR: CGM-Measured Differences in Pregnancies With vs. Without Gestational Diabetes (GDM) and Adverse Perinatal Outcomes (APO)

1174-P: Characterization of Glucose Levels in Pregnancy Measured by Blood Glucose Testing or CGM Monitoring after a 50-g Screening or a 75-g or 100-g OGTT

1031-P: Virtual Clinic Support—Patient-Reported Outcome Benefits

728-P: Glycemic Variability of Tirzepatide vs. Insulin Degludec in People with Type 2 Diabetes Using Continuous Glucose Monitoring (SURPASS-3 CGM)

105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Update search

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only